Analysts Offer Insights on Healthcare Companies: Myomo (MYO) and Accolade (ACCD)
Myomo Analyst Ratings
Lake Street Starts Myomo With Buy Rating, $7 Price Target
Myomo's Strategic Turnaround: A Buy Rating With Revenue Growth and Operational Scaling on the Horizon
Myomo Analyst Ratings
Myomo's Strong Growth Potential Amid New CMS Guidelines Elicits a Buy Rating
Myomo Inc.: Strong Growth and Regulatory Tailwinds Support Buy Rating
HC Wainwright & Co. Initiates Coverage On Myomo With Buy Rating, Announces Price Target of $6.5
Myomo Analyst Ratings
Maxim Group Keeps Their Buy Rating on Myomo (MYO)
Ascendiant Sticks to Its Buy Rating for Myomo (MYO)
Myomo (MYO) Receives a Buy From Maxim Group
Maxim Group Initiates Coverage On Myomo With Buy Rating, Announces Price Target of $2
Alliance Global Lowers Myomo's Price Target to $6.70 From $10, Maintains Buy Rating
Myomo Price Target Cut to $6.70/Share From $10.00 by Alliance Global Partners
Myomo Is Maintained at Buy by Alliance Global Partners
Myomo analyst ratings
Alliance Global Partners Maintains Buy on Myomo, Lowers Price Target to $6.7